Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Phase 1 Recruiting
51 enrolled
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Phase 1 Recruiting
57 enrolled
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
Phase 1 Recruiting
32 enrolled
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
Phase 2 Recruiting
200 enrolled
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
Phase 1 Recruiting
36 enrolled
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Phase 1 Recruiting
18 enrolled
PNeoVCA
Phase 1/2 Recruiting
132 enrolled
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
Phase 2 Recruiting
40 enrolled
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
Phase 1 Recruiting
43 enrolled
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Phase 3 Recruiting
1,295 enrolled
Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
Phase 2 Recruiting
30 enrolled
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer
Phase 1 Recruiting
60 enrolled
AVATAR
Phase NA Recruiting
110 enrolled
Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer
Phase 2 Recruiting
11 enrolled
An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer
Phase NA Recruiting
100 enrolled
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
Phase 1 Recruiting
54 enrolled
ELEPHAS-05
Recruiting
2,000 enrolled
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
Phase 2 Recruiting
100 enrolled
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
Phase 2 Recruiting
25 enrolled
TEODOR
Phase NA Recruiting
350 enrolled
Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
Recruiting
12 enrolled
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
Recruiting
10,000 enrolled
Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
Phase 1 Recruiting
24 enrolled
ONAC
Recruiting
58 enrolled
AI Model for Classifying Breast Cancer From Histopathology Images
Recruiting
500 enrolled
NEOEPICURE
Phase NA Recruiting
300 enrolled
PEAR-MET
Recruiting
30 enrolled